Table 3.
Demographic data of Thai breast cancer patients undergoing TAM treatment
| Demographic and clinical data | N (%) |
|---|---|
| Age (years) | |
| 18–30 | 1 (0.7) |
| 30–40 | 17 (12.7) |
| 40–50 | 54 (40.3) |
| >50 | 62 (46.3) |
| TAM administration (years) | |
| <0.5 | 26 (19.4) |
| 0.5–1 | 23 (17.2) |
| 1–3 | 57 (42.5) |
| >3 | 28 (20.9) |
| History of treatment | |
| Chemotherapy | 89 (17.6) |
| Operations | 43 (8.5) |
| Radiation | 42 (8.3) |
| Stage of breast cancer | |
| Stage 0 | 1 (0.7) |
| Stage I | 44 (32.8) |
| Stage II | 58 (43.3) |
| Stage III | 24 (17.9) |
| Stage IV | 6 (4.5) |
| Unidentified | 1 (0.7) |
| ER+ | 132 (98.5) |
| PR+ | 97 (72.4) |
| HER2+ | 76 (56.7) |
| Menopausal status | |
| Premenopausal | 71 (53.0) |
| Perimenopausal | 14 (10.4) |
| Postmenopausal | 49 (36.6) |
Abbreviations: TAM, tamoxifen; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.